ライフサイエンスコーパス: ciprofloxacin

1 nd breaks (ionizing radiation, UV radiation, ciprofloxacin).

2 ant antibiotics (penicillin G, tetracycline, ciprofloxacin).

3 m, 1.9-fold for vancomycin, and 3.9-fold for ciprofloxacin).

4 tics (moxifloxacin followed by ofloxacin and ciprofloxacin).

5 cally and were resistant to erythromycin and ciprofloxacin.

6 92% category agreement between ofloxacin and ciprofloxacin.

7 e of the more challenging compounds, such as ciprofloxacin.

8 key agar containing 1 mug/ml or 10 mug/ml of ciprofloxacin.

9 er risk of hypoglycemia than those receiving ciprofloxacin.

10 A/cm(2)) both in the presence and absence of ciprofloxacin.

11 eptible to trimethoprim-sulfamethoxazole and ciprofloxacin.

12 ore susceptible to killing by tobramycin and ciprofloxacin.

13 -16.0) for vancomycin, and 3.7 (3.0-5.6) for ciprofloxacin.

14 PFGE patterns and uniform susceptibility to ciprofloxacin.

15 the sensitivity of Pseudomonas aeruginosa to ciprofloxacin.

16 abrogated by cotreatment with the antibiotic ciprofloxacin.

17 P. aeruginosa EE and highly synergistic with ciprofloxacin.

18 e resistant to penicillin, tetracycline, and ciprofloxacin.

19 n of Neisseria gonorrhoeae susceptibility to ciprofloxacin.

20 se yields active enzyme that is resistant to ciprofloxacin.

21 sseria gonorrhoeae isolates are resistant to ciprofloxacin.

22 ed decreased susceptibility or resistance to ciprofloxacin.

23 istant or showed decreased susceptibility to ciprofloxacin.

24 tes of Indonesian origin were susceptible to ciprofloxacin.

25 omonas phage cocktail alone or combined with ciprofloxacin.

26 k for uveitis compared with moxifloxacin and ciprofloxacin.

27 n-polymyxin B-gramicidin in the Philippines; ciprofloxacin 0.3% in India).

28 cin disks detected all isolates resistant to ciprofloxacin (0% very major error) and yielded false re

29 36), gentamicin (0.89; 95%CI: 0.06-1.84) and ciprofloxacin (0%).

30 ing concentrations of the three antibiotics (ciprofloxacin ~0.0067 mg/ml, clarithromycin ~0.05 mg/ml,

31 S, S. aureus and other bacterial isolates to ciprofloxacin (11.1%-24.2%), gentamicin (5.6-31.0%), tob

32 istance to SMZ/TMP (75% vs. 80%; P=1.00) and ciprofloxacin (16.7% vs. 30%; P=0.39) in Groups 1 and 2.

33 52 (42%) to levofloxacin, 20 of 54 (37%) to ciprofloxacin, 16 of 47 (34%) to moxifloxacin, and 3 of

34 hours but were prevented by combination with ciprofloxacin (2.5 x minimum inhibitory concentration).

35 These were 10.68 (95% CI, 3.28-34.82) for ciprofloxacin, 2.41 (95% CI, .76-7.68) for levofloxacin,

36 r susceptibility pattern; amoxicillin 38.7%, ciprofloxacin 25.8%, chloramphinicol 25.8%, co-trimoxazo

37 Monday, Wednesday, Friday for 6 months plus ciprofloxacin 250 mg twice daily for 30 days (Group 2) o

38 greater activity than the parent antibiotic ciprofloxacin (30 mg/kg, 90.6 mumol/kg) given in multipl

39 l of 64.5% of CNS isolates were sensitive to ciprofloxacin; 30.1% of CNS isolates were resistant to >

40 red to inhibit 90% of isolates increased for ciprofloxacin (4 mug/mL from 1 mug/mL), erythromycin (25

41 Three compounds, ciprofloxacin, 4-nonylphenol (NP), and 4-tert-octylpheno

42 The resistance rate was 39% against ciprofloxacin, 44% against TMP-SMX, and 25% against cefu

43 ose of the study was to assess the effect of ciprofloxacin (500 mg twice daily for 10 days) or clinda

44 7.5%; levofloxacin, 58.5%; oxacillin, 54.7%; ciprofloxacin, 51.0%; gatifloxacin, 51.0%; and moxifloxa

45 3 secretion system+ isolates was observed to ciprofloxacin (59%), cefepime (35%), and gentamicin (38%

46 acin (400 mg once daily) monotherapy or oral ciprofloxacin (750 mg twice daily) plus amoxicillin/clav

47 le to the standard antibiotic treatment with ciprofloxacin (8 mg/kg, sc).

48 linical isolates were generally sensitive to ciprofloxacin (89.4% susceptible; 10.6% intermediate res

49 12 days for povidone-iodine and 17 days for ciprofloxacin (95% CI, -35.2 to 3.2 days).

50 wing: ceftazidime, 100%; levofloxacin, 100%; ciprofloxacin, 95.0%; tobramycin, 90.6%; gentamicin, 80.

51 with resistance based on characteristics of ciprofloxacin (A), azithromycin (B), and ceftriaxone (C)

52 usly increase solubility and permeability of ciprofloxacin, a biopharmaceutics classification system

53 The drug derivatives, consisting of ciprofloxacin, a perfluoroaryl ring, and a phenyl ring l

54 E. coli infections, RvD1 and the antibiotic ciprofloxacin accelerated resolution, each shortening re

55 when tested alone, were found to potentiate ciprofloxacin activity by a 4-fold increase at concentra

56 Current first-time users of ciprofloxacin (adjusted rate ratio, 1.96 [95% CI, 1.56-2

57 h a single treatment of chitosan followed by ciprofloxacin administration had a marked effect on redu

58 = .22), and small decreases in resistance to ciprofloxacin among CoNS and MRCoNS and to tobramycin am

59 Modeling of the transit of ciprofloxacin, an antibiotic of choice for treating Camp

60 In this study, we use ciprofloxacin, an organelle double-strand break-inducing

61 ociation was noted between clarithromycin or ciprofloxacin and adverse cardiac outcomes.

62 line acidifications and filtrations afforded ciprofloxacin and ciprofloxacin hydrochloride.

63 in-resistant Staphylococcus aureus (MRSA) to ciprofloxacin and clindamycin (which has a similar mode

64 etermination of oxolinic acid, danofloxacin, ciprofloxacin and enrofloxacin by micellar liquid chroma

65 Typhi strains with high-level resistance to ciprofloxacin and gatifloxacin had emerged.

66 radation and does not affect the activity of ciprofloxacin and gentamicin.

67 se in BK viral load in patients treated with ciprofloxacin and leflunomide (P<0.001) with only a smal

68 first time that, used in a stepwise fashion, ciprofloxacin and leflunomide are effective and safe tre

69 decreased eGFR (P<0.001), and treatment with ciprofloxacin and leflunomide was associated with improv

70 The side effects of ciprofloxacin and leflunomide were recorded in each pati

71 Categorical agreements for the ciprofloxacin and levofloxacin Etests were 89.6 and 83.7

72 Ciprofloxacin and levofloxacin susceptibility for all te

73 y was performed for the bioquantification of ciprofloxacin and marbofloxacin via HPTLC-Bacillus subti

74 .6 ng and 2 ng of the synthetic antibiotics, ciprofloxacin and marbofloxacin, respectively.

75 zathioprine surrogate), the fluoroquinolones ciprofloxacin and ofloxacin and vemurafenib.

76 hioprine and the fluoroquinolone antibiotics ciprofloxacin and ofloxacin interact with UVA radiation

77 UVA photoactivation of 6-TG, ciprofloxacin and ofloxacin was associated with the gene

78 Ciprofloxacin and pefloxacin provided clearer differenti

79 atients in the high exposure arm, the use of ciprofloxacin and piperacillin/tazobactam was 51% and 75

80 isodes of fluoroquinolone use (660,572 [88%] ciprofloxacin) and 5,520,446 control episodes of nonuse.

81 were only intermediate in susceptibility to ciprofloxacin, and 90% were resistant to metronidazole a

82 forward protocol from a perfluoroaryl azide, ciprofloxacin, and an aldehyde in acetone at room temper

83 ells to cis-DA led to a loss of tolerance to ciprofloxacin, and an increase of the bacterial fluoresc

84 with amoxicillin, azithromycin, clindamycin, ciprofloxacin, and doxycycline on blood-supplemented Mue

85 Here, we show that the FQ drugs norfloxacin, ciprofloxacin, and enrofloxacin are powerful iron chelat

86 , inhibitors of bacterial gyrase, GSK299423, ciprofloxacin, and etoposide exhibited 15-, 57-, and 3-f

87 confidence intervals (CIs) of levofloxacin, ciprofloxacin, and moxifloxacin compared with macrolides

88 reduced resistance to bactericidal levels of ciprofloxacin, and production of extracellular R2 pyocin

89 e different emerging contaminants (caffeine, ciprofloxacin, and propranolol) and two model compounds

90 nce determinants for different beta-lactams, ciprofloxacin, and tetracyclines on multiple occasions.

91 Current use of moxifloxacin or ciprofloxacin appears to increase the risk for uveitis.

92 oracarbef and the fluoroquinolone antibiotic ciprofloxacin are described.

93 amenting progeny with enhanced resistance to ciprofloxacin as the parent filament dies.

94 cus epidermidis biofilms in conjunction with ciprofloxacin at physiologic saline conditions meant to

95 istance across four antibiotics (tobramycin, ciprofloxacin, aztreonam, and imipenem), indicating that

96 We report the modular formulation of ciprofloxacin-based pure theranostic nanodrugs that disp

97 eptibility to the fluoroquinolone antibiotic ciprofloxacin by increased efflux.

98 levant antimicrobials (colistin, imipenem or ciprofloxacin) by Transposon Directed Insertion-site Seq

99 In areas of high fluoroquinolone resistance, ciprofloxacin can be used empirically when prior urine c

100 ial activities of various antibiotics (i.e., ciprofloxacin, ceftriaxone, and tetracycline) against Es

101 the SOS response by the genotoxic antibiotic ciprofloxacin changes the E. coli rod shape into multich

102 itive bacterial isolates were susceptible to ciprofloxacin, chloramphinicol, amoxicillin-clavulanate

103 nvestigated as an antimicrobial enhancer for ciprofloxacin (CIP) against a wild-type PA biofilm (stra

104 metabolites from ENR were identified, which ciprofloxacin (CIP) and desethylene-ENR were the major m

105 Ferrate can remove more than 80% of ciprofloxacin (CIP) at ferrate dose of 1 mg Fe/L and 30%

106 In this study, interactions of Ciprofloxacin (CIP), a fluoroquinolone antibiotic with t

107 Ciprofloxacin (CIP), danofloxacin (DAN), enrofloxacin (E

108 tolytic fate of the chlortetracycline (CTC), ciprofloxacin (CIP), roxarsone (ROX), and sulfamethoxazo

109 Overall ciprofloxacin (CIP), trimethoprim-sulfamethoxazole (SXT)

110 ive, C-7-modified chloroacetyl derivative of ciprofloxacin (Cip-AcCl) formed cross-linked cleaved com

111 dinitrophenyl (DNP) moiety to the C7 end of ciprofloxacin (Cip-DNP) reduced protection due to resist

112 quatic environments, enrofloxacin (ENRO) and ciprofloxacin (CIPRO), were chosen as nonresonant molecu

113 ion of the MIC mode) was found for amikacin, ciprofloxacin, clarithromycin, and moxifloxacin.

114 ting of the clinically important antibiotics ciprofloxacin, clarithromycin, and rifampicin in the cas

115 loxacin, while MSSA became more resistant to ciprofloxacin, clindamycin, gentamicin sulfate, and trim

116 onstrated increased antibiotic resistance to ciprofloxacin, clindamycin, gentamicin, and trimethoprim

117 for susceptibility to ampicillin, cefazolin, ciprofloxacin, colistin, gentamicin, meropenem, and tetr

118 Moreover, phage/ciprofloxacin combinations were highly synergistic, kill

119 differences in log reductions for wells with ciprofloxacin compared to those without at the same curr

120 the clinical cure rate was 83% (124/150) for ciprofloxacin compared with 71% (106/150) for cefpodoxim

121 robiological cure rate was 96% (123/128) for ciprofloxacin compared with 81% (104/129) for cefpodoxim

122 s having clinical cure was 93% (139/150) for ciprofloxacin compared with 82% (123/150) for cefpodoxim

123 chitosan in conjunction with the antibiotic ciprofloxacin completely eradicates UPEC from the urinar

124 (P > 0.1) between the culture methods or the ciprofloxacin concentrations in the medium when identify

125 cribe a novel osteoadsorptive bisphosphonate-ciprofloxacin conjugate (BV600022), utilizing a "target

126 Patients with any ciprofloxacin-containing antibiotic regimen the first 3

127 Patients with ciprofloxacin-containing regimens had higher risk of inv

128 ERFX and its metabolite, ciprofloxacin (CPFX), have been reported to accumulate i

129 nolones used in the veterinary field such as ciprofloxacin (CPFX, IC(50), 0.35 mug L(-1)), enrofloxac

130 sily applicable by user for the detection of ciprofloxacin (CPX) molecule in water resources.

131 Norfloxacin and ciprofloxacin - d8 were used as internal standards to qu

132 ized the cells to ionizing radiation, UV and ciprofloxacin damage, indicating that these two genes ha

133 associated with decreased susceptibility to ciprofloxacin (DCS).

134 into stable nanoaggregates that transformed ciprofloxacin derivatives into AIE-active luminogens.

135 a 3-day regimen of cefpodoxime compared with ciprofloxacin did not meet criteria for noninferiority f

136 Levels of induction of toxin production by ciprofloxacin differed among the strains tested, with mo

137 ing reactions were observed: enrofloxacin-to-ciprofloxacin, difloxacin-to-sarafloxacin, and pefloxaci

138 olates are difficult to detect with standard ciprofloxacin disk diffusion, and plasmid-mediated resis

139 enteric rods/pseudomonads were subjected to ciprofloxacin disk-diffusion testing.

140 82.6%, 67.8%, and 23.5% were susceptible to ciprofloxacin, erythromycin, and penicillin, respectivel

141 olates from 1990 through 2001, occurred with ciprofloxacin, erythromycin, and penicillin.

142 cs, ampicillin, amoxicillin/clavulanate, and ciprofloxacin exhibited marked in vitro inhibitory activ

143 Of these, oxytetracycline and ciprofloxacin exhibited the greater reduction rate of 23

144 genetic interactions for survival to AZT or ciprofloxacin exposure were observed between RadA and kn

145 Nine of 10 patients treated with ciprofloxacin for >/=10 days recovered uneventfully, wit

146 g trends in resistance to nalidixic acid and ciprofloxacin for both ST and SPA.

147 roquinolone-resistant mutant, the potency of ciprofloxacin for inhibition of supercoiling and stabili

148 Prior to biopsy, patients are commonly given ciprofloxacin for prophylaxis.

149 nificantly enhanced therapeutic index versus ciprofloxacin for the treatment of osteomyelitis in vivo

150 prim-sulfamethoxazole , multidrug), or >70% (ciprofloxacin, gentamicin) of total antimicrobial resist

151 Ciprofloxacin, gentamicin, tobramycin and vancomycin sho

152 At first follow-up, 16% of women in the ciprofloxacin group compared with 40% of women in the ce

153 liana mutant resistant to the quinolone drug ciprofloxacin has a point mutation in ATGYRA.

154 xone > tautetracycline) again indicated that ciprofloxacin has more bactericidal activity than the ot

155 Fluoroquinolones (e.g., ciprofloxacin) have become a mainstay for treating sever

156 sensing of biologically active drug molecule ciprofloxacin hydrochloride (CFX).

157 urrent use of moxifloxacin, levofloxacin, or ciprofloxacin hydrochloride was compared with nonuse.

158 s and filtrations afforded ciprofloxacin and ciprofloxacin hydrochloride.

159 have studied the fluoroquinolone antibiotic ciprofloxacin in an animal model for complicated Salmone

160 ly classified as susceptible or resistant to ciprofloxacin in less than 10 min.

161 Ciprofloxacin increased the sensitivity of cancer cell l

162 Also, the addition of ciprofloxacin induced a highly selective fluorescence en

163 In conclusion, this study demonstrates a ciprofloxacin-induced reversible reduction of the normal

164 Stx2a levels after ciprofloxacin induction were lower for PA2 than for the

165 (P = .028) and an increase at 5 months after ciprofloxacin intake to 4.88% +/- 1.02.

166 whole tendon (from baseline to 10 days after ciprofloxacin intake, 130 arbitrary units [au] +/- 8 to

167 ter ciprofloxacin intake, and 5 months after ciprofloxacin intake, 134 au +/- 8, 105 au +/- 5, and 11

168 th a decrease from baseline to 10 days after ciprofloxacin intake, 4.74% +/- 0.75 to 4.50% +/- 0.23,

169 he tendon insertion (baseline, 10 days after ciprofloxacin intake, and 5 months after ciprofloxacin i

170 of GAG content in the Achilles tendon after ciprofloxacin intake.

171 n at baseline and 10 days and 5 months after ciprofloxacin intake.

172 atory Standards Institute (CLSI) revised the ciprofloxacin interpretive criteria (breakpoints) for di

173 nically relevant antibiotics, tobramycin and ciprofloxacin, into non-mucoid Pseudomonas aeruginosa bi

174 Ciprofloxacin is a recommended treatment for Shigella in

175 unds, whereas resistance to tetracycline and ciprofloxacin is largely due to the activity of efflux p

176 In this context, ciprofloxacin is part of the first-line of countermeasur

177 , for the three antibiotics, indicating that ciprofloxacin is the most effective against this E. coli

178 Ciprofloxacin is the standard treatment in self-therapy

179 MICs ranging from 0.12 to 0.25 mg/liter for ciprofloxacin (just above the wild-type MIC of </=0.06 m

180 re MIC tested by broth microdilution against ciprofloxacin, levofloxacin, and ofloxacin and by disk d

181 The MICs for ciprofloxacin, levofloxacin, and ofloxacin were >32 mug/

182 nhibition zone diameters for nalidixic acid, ciprofloxacin, levofloxacin, and ofloxacin were determin

183 The addition of a 30-day course of ciprofloxacin lowered the incidence of UTI; randomized p

184 SI rates, including cefazolin/metronidazole, ciprofloxacin/metronidazole, and ertapenem.

185 ory agreement (94%) when plotted against the ciprofloxacin MICs and that the new ofloxacin MIC breakp

186 including 111 with intermediate or resistant ciprofloxacin MICs mediated by a variety of resistance m

187 These data suggest that ciprofloxacin monotherapy as a prophylaxis regimen prior

188 untreated controls) and was comparable with ciprofloxacin monotherapy.

189 2007, outpatient new users of levofloxacin, ciprofloxacin, moxifloxacin, cephalosporins, and macroli

190 re to colistin (n = 35), imipenem (n = 1) or ciprofloxacin (n = 1) in addition to known resistance de

191 with acute uncomplicated cystitis comparing ciprofloxacin (n = 150) with cefpodoxime (n = 150); pati

192 idal activity of the nanosphere-encapsulated ciprofloxacin (nanosphere/cipro) was tested by using liq

193 evaluate anaphylactoid reactions induced by ciprofloxacin, norfloxacin, lomefloxacin, moxifloxacin,

194 Ciprofloxacin, ofloxacin, and pefloxacin disks detected

195 ppears that clindamycin has more impact than ciprofloxacin on the intestinal microbiota.

196 cular assemblies of two crystalline forms of Ciprofloxacin: one anhydrate and one hydrate forming wat

197 Exposure to ciprofloxacin or clindamycin had a strong effect on the

198 the normal microbiota to be normalized after ciprofloxacin or clindamycin treatment differed for vari

199 clarithromycin, moxifloxacin, levofloxacin, ciprofloxacin, or amoxicillin-clavulanate at outpatient

200 me in the presence or absence of penicillin, ciprofloxacin, or doxycycline.

201 Patients were given 250 mg of ciprofloxacin orally twice daily for 3 days or 100 mg of

202 nce of colloids promotes the breakthrough of ciprofloxacin (over 90% sorbed on colloids) from ~4% to

203 trimethoprim-sulfamethoxazole (P = .01), and ciprofloxacin (P = .03) than that from group A.

204 portion of exoU(+) strains were resistant to ciprofloxacin (p = 0.001), gatifloxacin (p = 0.003), and

205 m MSM had a high prevalence of resistance to ciprofloxacin, penicillin, and tetracycline and were sig

206 or four of the six antibiotics (clindamycin, ciprofloxacin, penicillin-G, and trimethoprim).

207 xacin, ciprofloxacin plus hydrocortisone, or ciprofloxacin plus dexamethasone) or neomycin plus hydro

208 ocortisone, and 2.00 (95% CI, 1.18-3.41) for ciprofloxacin plus dexamethasone.

209 for ofloxacin, 1.94 (95% CI, 1.32-2.85) for ciprofloxacin plus hydrocortisone, and 2.00 (95% CI, 1.1

210 cluded ear drops were quinolones (ofloxacin, ciprofloxacin plus hydrocortisone, or ciprofloxacin plus

211 inate transcriptional regulatory gene, under ciprofloxacin pressure.

212 Upon addition of ciprofloxacin, PVD showed new UV-vis absorption bands at

213 film periphery, while the neutral antibiotic ciprofloxacin readily penetrated.

214 unit of PVD generates a converging cleft for ciprofloxacin recognition with LOD and LOQ of 7.13muM an

215 In contrast to ciprofloxacin, religation of the cleaved DNA did not occ

216 t solids may cause slight underestimation of ciprofloxacin removal efficiency.

217 60, ST-464, and ST-607) were associated with ciprofloxacin resistance (P < 0.05).

218 etection of genetic variants known to confer ciprofloxacin resistance in Bacillus anthracis, Yersinia

219 Tetracycline, erythromycin, sulfonamide, and ciprofloxacin resistance in soil was assessed using stan

220 Despite high local rates of ciprofloxacin resistance in urine isolates across all pa

221 aled that, comparing 2004-2009 to 2010-2012, ciprofloxacin resistance increased among domestic infect

222 oss all patients (40%; 95% CI, 39.5%-40.5%), ciprofloxacin resistance was <20% among patients with a

223 T-90, ST-91, and ST-97 (n = 162; 94.2%); and ciprofloxacin resistance was associated with NG-STAR ST-

224 All strains were ciprofloxacin resistant and metronidazole susceptible, a

225 VRE), and ceftazidime-resistant (CAZ(r)) and ciprofloxacin-resistant (CIP(r)) Gram-negative bacteria

226 eport a case of surgical site infection with ciprofloxacin-resistant Aeromonas hydrophila following l

227 children (19%) and 8 mothers (20%) excreted ciprofloxacin-resistant E. coli at least once.

228 least 1 member whose stool specimen yielded ciprofloxacin-resistant E. coli on culture.

229 Ciprofloxacin-resistant E. coli were usually resistant t

230 y children and their mothers commonly harbor ciprofloxacin-resistant E. coli with pathogenic potentia

231 In order to identify patients carrying ciprofloxacin-resistant E. coli, so as to tailor their a

232 roach in identifying patients colonized with ciprofloxacin-resistant E. coli.

233 ciated with subsequent childhood carriage of ciprofloxacin-resistant E. coli; antibiotic use, acid su

234 in the medium when identifying patients with ciprofloxacin-resistant E. coli; however, broth enrichme

235 er thousand vs 3.6 per thousand; p < 0.001), ciprofloxacin-resistant Enterobacteriaceae (0.8 per thou

236 The reservoir of pathogenic ciprofloxacin-resistant Escherichia coli remains unknown

237 tool specimens were cultured selectively for ciprofloxacin-resistant gram-negative bacteria.

238 ncluded in the study, 20 were colonized with ciprofloxacin-resistant organisms, 19 of which were E. c

239 plication of the procedure is infection with ciprofloxacin-resistant organisms, in particular resista

240 per thousand vs 2.5 per thousand; p = 0.02), ciprofloxacin-resistant Pseudomonas aeruginosa (0.5 per

241 riving the current intercontinental surge of ciprofloxacin-resistant S. sonnei and is capable of esta

242 However, ciprofloxacin-resistant S. sonnei are being increasingly

243 s into a global phylogeny, we found that all ciprofloxacin-resistant S. sonnei formed a single clade

244 encing on a collection of 60 contemporaneous ciprofloxacin-resistant S. sonnei isolated in four count

245 y hub for the recent international spread of ciprofloxacin-resistant S. sonnei.

246 s to determine the frequency of excretion of ciprofloxacin-resistant, potentially pathogenic E. coli.

247 Similarly, resistance to ciprofloxacin rose from 2.5% to 31.1% in E coli, from 1.

248 Host-directed RvD1 actions enhanced ciprofloxacin's therapeutic actions.

249 The three product antibiotics, namely ciprofloxacin, sarafloxacin, and norfloxacin, were found

250 istance was <20% among patients with a prior ciprofloxacin sensitive organism and no subsequent fluor

251 d ST-677) were significantly associated with ciprofloxacin sensitivity (P < 0.05).

252 ince it was reported that quinolones such as ciprofloxacin show antitrypanosomal activity, a novel qu

253 Ciprofloxacin showed superior microbiological, but not c

254 rates of multidrug resistance and decreased ciprofloxacin susceptibility (DCS) were 37.8% and 37.2%,

255 e evaluated a real-time PCR assay to predict ciprofloxacin susceptibility using residual DNA from the

256 MRSA was identified in 1,998 specimens, and ciprofloxacin-susceptible (CSMRSA) isolates (385/1,998,

257 when prior urine culture results indicate a ciprofloxacin-susceptible organism and there has been no

258 y either S. constellatus (45 individuals) or ciprofloxacin-susceptible strains of Gram-negative enter

259 ide polymorphisms (SNP) and deletions within ciprofloxacin targeted genes.

260 cies of three antibiotics (sulfamethoxazole, ciprofloxacin, tetracycline) in pilot- and full-scale bi

261 t at subminimal inhibitory concentrations of ciprofloxacin the bacterial filament divides asymmetrica

262 bacteria to nutrient broth and penicillin or ciprofloxacin, the authors were able to distinguish in s

263 iral load did not decrease after 2 months of ciprofloxacin therapy.

264 he risk gradually increased with duration of ciprofloxacin therapy: six of 384 in patients not expose

265 ase that is the target of the quinolone drug ciprofloxacin; this has important consequences for plant

266 The antibiotic-treated plants translocated ciprofloxacin through their tissues to roots, shoots, an

267 and PDO300 to multiple antibiotics including ciprofloxacin, tobramycin, tetracycline, and gentamicin.

268 First, we show that in why1why3polIb-1 and ciprofloxacin-treated plants, plastid genome instability

269 nse, finding that one subpopulation survives ciprofloxacin treatment better than the other.

270 High-dose ciprofloxacin treatment efficiently reduced pathogen loa

271 This bimodal response to ciprofloxacin treatment in A. baumannii is unique and qu

272 nes examined respond in a bimodal fashion to ciprofloxacin treatment, forming two phenotypic subpopul

273 letion mutant strains were more resistant to ciprofloxacin treatment.

274 Removal of acetaminophen, ciprofloxacin, trimethoprim, propranolol, and carbamazep

275 nts on any antibiotic regimen not containing ciprofloxacin (unadjusted hazard ratio = 3.7; 95% CI, 1.

276 oward H(2)O(2), vancomycin, norfloxacin, and ciprofloxacin under anaerobic conditions.

277 Ciprofloxacin used at study entry independently predicte

278 in, erythromycin, clindamycin, tetracycline, ciprofloxacin, vancomycin, trimethoprim, gentamicin, fus

279 cellent adsorption capacity (235.6 mg/g) for ciprofloxacin via combined adsorption interaction mechan

280 onto MacConkey agar containing 10 mug/ml of ciprofloxacin was 100% specific and missed only 1 positi

281 The association constant (Ka) of PVD with ciprofloxacin was calculated to be as low as 1.40x10(5)M

282 ocal drug delivery system for the antibiotic ciprofloxacin was developed with the aim of fighting bac

283 residence time of 9 min, the sodium salt of ciprofloxacin was prepared from simple building blocks v

284 Oxidation of ranitidine, cimetidine, and ciprofloxacin was primarily attributed to reaction with

285 Ciprofloxacin was started when the BK viral load was gre

286 In empiric therapy, ciprofloxacin was the first choice of drug (27%), follow

287 Removal efficiency of ciprofloxacin was the highest among the target compounds

288 li; however, broth enrichment using 1 mug/ml ciprofloxacin was the most sensitive at 100%, but it was

289 =7.38; 95% CI, 2.30-23.70); moxifloxacin and ciprofloxacin were also associated with elevated rates o

290 9 days), carbamazepine (355-1,624 days), and ciprofloxacin were not affected by wastewater irrigation

291 tetracycline, norfloxacylin, ceftriaxone and ciprofloxacin were observed among Gram negative bacteria

292 15%, n = 590) with reduced susceptibility to ciprofloxacin were obtained, among which 14 harboured PM

293 c cells, remained genetically susceptible to ciprofloxacin, were sufficient to reinitiate infection a

294 The antibacterial activity of ciprofloxacin, when used in combination with some of the

295 Both isolates were resistant to ciprofloxacin, which has not been previously reported.

296 MRSA became more sensitive to ciprofloxacin, while MSSA became more resistant to cipro

297 this increase, MRSA became more sensitive to ciprofloxacin, while MSSA demonstrated increased antibio

298 istant to metronidazole, aminoglycosides and ciprofloxacin with L. acidophilus being susceptible to p

299 urthermore, our data show that resistance to ciprofloxacin within S. sonnei may be globally attribute

300 Ideally, use of ciprofloxacin would be prefaced with AR determination to